Pseudomonas aeruginosa ventilator-associated pneumonia rabbit model for preclinical drug development

Keyphrases

• Rabbit Model 100%
• Pseudomonas Aeruginosa (P. aeruginosa) 100%
• Preclinical Development 100%
• Ventilator-associated Pneumonia 100%
• Humanized 80%
• Meropenem 80%
• Supportive Care 60%
• Intensive Care Unit 60%
• Placebo 40%
• Dosing Regimen 40%
• Acute Respiratory Distress Syndrome 40%
• Systemic Hypotension 20%
• Hypotension 20%
• Antibiotics 20%
• Large Animal Model 20%
• Plasma Concentration 20%
• Neutropenia 20%
• Disease Progression 20%
• Lung 20%
• Clinical Features 20%
• Antibiotic Efficacy 20%
• β-lactam Antibiotics 20%
• Predictive Power 20%
• FiO2 20%
• Leukopenia 20%
• Acute Lung Injury 20%
• Low Tidal Volume 20%
• Arterial Oxygen Partial Pressure 20%
• Hyperlactatemia 20%
• Bacterial Dissemination 20%
• Efficacy Testing 20%
• Acute Lung Inflammation 20%
• Antipseudomonal 20%
• Multiple Organ Dysfunction 20%
• Inspired Oxygen 20%
• Natural Disease 20%
• New Drug Candidate 20%
• PaO2 20%
• Concentrations-time Profiles 20%
• Fluid Challenge 20%
• Thrombocytopenia 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Drug Development 100%
• Pseudomonas aeruginosa 100%
• Rabbit Model 100%
• Ventilator Associated Pneumonia 100%
• Meropenem 80%
• Hypotension 40%
• Placebo 40%
• Adult Respiratory Distress Syndrome 40%
• Biological Marker 20%
• Neutropenia 20%
• Bacterial Pneumonia 20%
• Leporidae 20%
• Noradrenalin 20%
• Disease Exacerbation 20%
• Clinical Feature 20%
• Beta Lactam Antibiotic 20%
• Pneumonia 20%
• Acute Lung Injury 20%
• Hyperlactatemia 20%
• Thrombocytopenia 20%
• Leukopenia 20%
• Table Salt 20%